This text is a result of machine translation.
We-Linking Raised Over CNY 10 Mn in Angel Round
Intraoperative Neurophysiological Monitoring Equipment Developer NeuroFlag Closed An Angel Round
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
ZD Medtech Raised Over CNY 100 Mn in Series B
Smart Powered Bionic Prosthetic Star BionicM Nets Over CNY 10 Mn
Medical Technology Company MacroLux Nets Nearly CNY 100 Mn in Series A
ForLong Biotech Nets Over CNY 100 Mn in Series A
Taier shares: the contract dispute case against Cao Linbin was accepted by the court
Surgerii Robotics: Single-Port Surgical Robots Poised to Transform Surgery
The worldwide surgical robotic market is expected to grow at a booming CAGR of 5.8% during 2022 to 2030, rising from USD 5.05 billion in 2022 to USD 21.41 billion in 2030. Of which, the single-port surgical robots that result in less pain, fewer scars, and quicker recovery, have tremendous up potential.
Updated 5 hours ago
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Yunnan Baiyao: An Oriental Mystery in the Limelight (2/2)
Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.
May 19, 2020 12:30 PM
Yunnan Baiyao: An Oriental Mystery in the Limelight (1/2)
Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.
May 19, 2020 12:00 PM
Economic Daily: enterprise investment should not abandon the main business
Yunnan Baiyao responded that it lost 1.5 billion in stock speculation: it will gradually optimize the structure and gradually withdraw from securities investment
August 30 stock market lightning rod
The first bank of China fund to release its second Quarterly Report